Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Is Premorbid Functioning a Predictor of Outcome in Patients With Early Onset Psychosis Treated With Risperdal Consta?

NCT00369239 is registered in ClinicalTrials.gov with Janssen Pharmaceutica N.V., Belgium as lead sponsor.

NCT NCT00369239
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00369239 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Is Premorbid Functioning a Predictor of Outcome in Patients With Early Onset Psychosis Treated With Risperdal Consta?
Lead sponsor
Janssen Pharmaceutica N.V., Belgium
Phase
Phase 4
Overall status
Completed
Start date
March 31, 2006
Completion date
November 30, 2007
Enrollment
303 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

psychotic disorders, schizoaffective disorder, schizophrenia